Jaakkola, P., D.R. Mole, Y.M. Tian, M.I. Wilson, J. Gielbert, S.J. Gaskell, A. von Kriegsheim, H.F. Hebestreit, M. Mukherji, C.J. Schofield, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468–472.
Masson, N., C. Willam, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO Journal 20: 5197–5206.
Maynard, M.A., H. Qi, J. Chung, E.H. Lee, Y. Kondo, S. Hara, R.C. Conaway, J.W. Conaway, and M. Ohh. 2003. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Journal of Biological Chemistry 278: 11032–11040.
Xu, M.M., J. Wang, and J.X. Xie. 2017. Regulation of iron metabolism by hypoxia-inducible factors. Sheng Li Xue Bao 69: 598–610.
Sang, N., J. Fang, V. Srinivas, I. Leshchinsky, and J. Caro. 2002. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Molecular and Cellular Biology 22: 2984–2992.
Lando, D., D.J. Peet, D.A. Whelan, J.J. Gorman, and M.L. Whitelaw. 2002. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858–861.
Stolze, I., U. Berchner-Pfannschmidt, P. Freitag, C. Wotzlaw, J. Rossler, S. Frede, H. Acker, and J. Fandrey. 2002. Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. Blood 100: 2623–2628.
Arany, Z., L.E. Huang, R. Eckner, S. Bhattacharya, C. Jiang, M.A. Goldberg, H.F. Bunn, and D.M. Livingston. 1996. An essential role for p300/CBP in the cellular response to hypoxia. Proceedings of the National Academy of Sciences of the USA 93: 12969–12973.
Bhattacharya, S., C.L. Michels, M.K. Leung, Z.P. Arany, A.L. Kung, and D.M. Livingston. 1999. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes & Development 13: 64–75.
Shimoda, L.A., and G.L. Semenza. 2011. HIF and the lung: Role of hypoxia-inducible factors in pulmonary development and disease. American Journal of Respiratory and Critical Care Medicine 183: 152–156.
Semenza, G.L. 2014. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annual Review of Pathology: Mechanisms of Disease 9: 47–71.
Meyrick, B., and L. Reid. 1980. Endothelial and subintimal changes in rat hilar pulmonary artery during recovery from hypoxia. A quantitative ultrastructural study. Laboratory Investigation 42: 603–615.
Stenmark, K.R., B. Meyrick, N. Galie, W.J. Mooi, and I.F. McMurtry. 2009. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. American Journal of Physiology. Lung Cellular and Molecular Physiology 297: L1013-1032.
Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16: 4604–4613.
Kouvaras, E., Z. Christoni, I. Siasios, K. Malizos, G.K. Koukoulis, and M. Ioannou. 2019. Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors. Biotechnic and Histochemistry 94: 283–289.
Li, J., S.X. Li, X.H. Gao, L.F. Zhao, J. Du, T.Y. Wang, L. Wang, J. Zhang, H.Y. Wang, R. Dong, and Z.Y. Guo. 2019. HIF1A and VEGF regulate each other by competing endogenous RNA mechanism and involve in the pathogenesis of peritoneal fibrosis. Pathology, Research and Practice 215: 644–652.
Ceradini, D.J., A.R. Kulkarni, M.J. Callaghan, O.M. Tepper, N. Bastidas, M.E. Kleinman, J.M. Capla, R.D. Galiano, J.P. Levine, and G.C. Gurtner. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine 10: 858–864.
Labrousse-Arias, D., R. Castillo-Gonzalez, N.M. Rogers, M. Torres-Capelli, B. Barreira, J. Aragones, A. Cogolludo, J.S. Isenberg, and M.J. Calzada. 2016. HIF-2alpha-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction. Cardiovascular Research 109: 115–130.
Gras, E., E. Belaidi, A. Briancon-Marjollet, J.L. Pepin, C. Arnaud, and D. Godin-Ribuot. 1985. (2016) Endothelin-1 mediates intermittent hypoxia-induced inflammatory vascular remodeling through HIF-1 activation. Journal of Applied Physiology 120: 437–443.
Choi, C.W., J. Lee, H.J. Lee, H.S. Park, Y.S. Chun, and B.I. Kim. 2015. Deferoxamine improves alveolar and pulmonary vascular development by upregulating hypoxia-inducible factor-1alpha in a rat model of bronchopulmonary dysplasia. Journal of Korean Medical Science 30: 1295–1301.
Vadivel, A., R.S. Alphonse, N. Etches, T. van Haaften, J.J. Collins, M. O’Reilly, F. Eaton, and B. Thebaud. 2014. Hypoxia-inducible factors promote alveolar development and regeneration. American Journal of Respiratory Cell and Molecular Biology 50: 96–105.
Tibboel, J., F.A. Groenman, J. Selvaratnam, J. Wang, I. Tseu, Z. Huang, I. Caniggia, D. Luo, M. van Tuyl, C. Ackerley, J.C. de Jongste, D. Tibboel, and M. Post. 2015. Hypoxia-inducible factor-1 stimulates postnatal lung development but does not prevent O2-induced alveolar injury. American Journal of Respiratory Cell and Molecular Biology 52: 448–458.
Yu, A.Y., L.A. Shimoda, N.V. Iyer, D.L. Huso, X. Sun, R. McWilliams, T. Beaty, J.S. Sham, C.M. Wiener, J.T. Sylvester, and G.L. Semenza. 1999. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. The Journal of Clinical Investigation 103: 691–696.
Brusselmans, K., V. Compernolle, M. Tjwa, M.S. Wiesener, P.H. Maxwell, D. Collen, and P. Carmeliet. 2003. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. The Journal of Clinical Investigation 111: 1519–1527.
Steiner, M.K., O.L. Syrkina, N. Kolliputi, E.J. Mark, C.A. Hales, and A.B. Waxman. 2009. Interleukin-6 overexpression induces pulmonary hypertension. Circulation Research 104: 236–244, 228p following 244.
Frid, M.G., J.A. Brunetti, D.L. Burke, T.C. Carpenter, N.J. Davie, J.T. Reeves, M.T. Roedersheimer, N. van Rooijen, and K.R. Stenmark. 2006. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. American Journal of Pathology 168: 659–669.
Epelman, S., K.J. Lavine, and G.J. Randolph. 2014. Origin and functions of tissue macrophages. Immunity 41: 21–35.
Samanta, D., and G.L. Semenza. 2017. Maintenance of redox homeostasis by hypoxia-inducible factors. Redox Biology 13: 331–335.
Li, Y., A. Jia, Y. Wang, L. Dong, Y. Wang, Y. He, S. Wang, Y. Cao, H. Yang, Y. Bi, and G. Liu. 2019. Immune effects of glycolysis or oxidative phosphorylation metabolic pathway in protecting against bacterial infection. Journal of Cellular Physiology 234: 20298–20309.
Semenza, G.L., P.H. Roth, H.M. Fang, and G.L. Wang. 1994. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry 269: 23757–23763.
Semenza, G.L., B.H. Jiang, S.W. Leung, R. Passantino, J.P. Concordet, P. Maire, and A. Giallongo. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Journal of Biological Chemistry 271: 32529–32537.
Rodriguez-Prados, J.C., P.G. Traves, J. Cuenca, D. Rico, J. Aragones, P. Martin-Sanz, M. Cascante, and L. Bosca. 2010. Substrate fate in activated macrophages: A comparison between innate, classic, and alternative activation. The Journal of Immunology 185: 605–614.
Kim, J.W., I. Tchernyshyov, G.L. Semenza, and C.V. Dang. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 3: 177–185.
Iyer, N.V., L.E. Kotch, F. Agani, S.W. Leung, E. Laughner, R.H. Wenger, M. Gassmann, J.D. Gearhart, A.M. Lawler, A.Y. Yu, and G.L. Semenza. 1998. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes & Development 12: 149–162.
Cheng, S.C., J. Quintin, R.A. Cramer, K.M. Shepardson, S. Saeed, V. Kumar, E.J. Giamarellos-Bourboulis, J.H. Martens, N.A. Rao, A. Aghajanirefah, G.R. Manjeri, Y. Li, D.C. Ifrim, R.J. Arts, B.M. van der Veer, P.M. Deen, C. Logie, L.A. O’Neill, P. Willems, F.L. van de Veerdonk, J.W. van der Meer, A. Ng, L.A. Joosten, C. Wijmenga, H.G. Stunnenberg, R.J. Xavier, and M.G. Netea. 2014. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345: 1250684.
Eckle, T., K. Brodsky, M. Bonney, T. Packard, J. Han, C.H. Borchers, T.J. Mariani, D.J. Kominsky, M. Mittelbronn, and H.K. Eltzschig. 2013. HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biology 11: e1001665.
Selak, M.A., S.M. Armour, E.D. MacKenzie, H. Boulahbel, D.G. Watson, K.D. Mansfield, Y. Pan, M.C. Simon, C.B. Thompson, and E. Gottlieb. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77–85.
Tannahill, G.M., A.M. Curtis, J. Adamik, E.M. Palsson-McDermott, A.F. McGettrick, G. Goel, C. Frezza, N.J. Bernard, B. Kelly, N.H. Foley, L. Zheng, A. Gardet, Z. Tong, S.S. Jany, S.C. Corr, M. Haneklaus, B.E. Caffrey, K. Pierce, S. Walmsley, F.C. Beasley, E. Cummins, V. Nizet, M. Whyte, C.T. Taylor, H. Lin, S.L. Masters, E. Gottlieb, V.P. Kelly, C. Clish, P.E. Auron, R.J. Xavier, and L.A. O’Neill. 2013. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496: 238–242.
D’Alessandro, A., H.B. Moore, E.E. Moore, J.A. Reisz, M.J. Wither, A. Ghasasbyan, J. Chandler, C.C. Silliman, K.C. Hansen, and A. Banerjee. 2017. Plasma succinate is a predictor of mortality in critically injured patients. Journal of Trauma and Acute Care Surgery 83: 491–495.
Zhang, H., M. Bosch-Marce, L.A. Shimoda, Y.S. Tan, J.H. Baek, J.B. Wesley, F.J. Gonzalez, and G.L. Semenza. 2008. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. Journal of Biological Chemistry 283: 10892–10903.
Zhang, H., P. Gao, R. Fukuda, G. Kumar, B. Krishnamachary, K.I. Zeller, C.V. Dang, and G.L. Semenza. 2007. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407–420.
Hacker, H., and M. Karin. 2006. Regulation and function of IKK and IKK-related kinases. Sciences STKE 2006: re13.
Rius, J., M. Guma, C. Schachtrup, K. Akassoglou, A.S. Zinkernagel, V. Nizet, R.S. Johnson, G.G. Haddad, and M. Karin. 2008. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807–811.
Jiang, H., Y.S. Zhu, H. Xu, Y. Sun, and Q.F. Li. 2010. Inflammatory stimulation and hypoxia cooperatively activate HIF-1 in bronchial epithelial cells: Involvement of PI3K and NF-B. American Journal of Physiology. Lung Cellular and Molecular Physiology 298: L660-669.
van Uden, P., N.S. Kenneth, and S. Rocha. 2008. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. The Biochemical Journal 412: 477–484.
Bandarra, D., J. Biddlestone, S. Mudie, H.A. Muller, and S. Rocha. 2015. HIF-1alpha restricts NF-kappaB-dependent gene expression to control innate immunity signals. Disease Models & Mechanisms 8: 169–181.
留言 (0)